US spot Bitcoin ETFs experienced a sharp reversal with $450 million in outflows from September 8-10, erasing nearly half of the previous week's $987 million inflows. The sell-off accelerated, peaking at $282.6 million in redemptions on September 10, led mainly by the ARK 21Shares Bitcoin ETF. Bitcoin's price dropped below $80,000 during this period, reflecting the negative sentiment. Despite strong cumulative inflows since January 2024, 2026 has seen net outflows of about $1.07 billion, signaling increased investor caution amid volatile market conditions.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
